On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now Blog

All posts by Christopher

Pressure BioSciences Inc.’s (PBIO) PCT Platform Featured in 15 Independent Scientific Presentations

  • The presentations were held during the annual American Society of Mass Spectrometry conference – an event attended by more than 10,000 scientists
  • Research focused on a wide range of applications ranging from cancer research to biomarker discovery
  • The number of PCT-related presentations during the 2019 conference exceeded prior Pressure BioSciences records for a scientific meeting, demonstrating the platform’s broad applicability potential

Pressure BioSciences Inc.’s (OTCQB: PBIO) patented pressure cycling technology (PCT) platform was featured prominently in 15 independent scientific presentations delivered during the annual conference of the American Society of Mass Spectrometry (ASMS) that took place June 1-6, 2019 in Atlanta, Georgia, as the company announced in a recent press release (http://ibn.fm/vLiCW).

The ASMS annual meeting is a highly reputable conference attended by more than 10,000 scientists from around the world. It is a showcase event for new research and scientific findings that has been held every year since 1953.

This year’s PCT-involving presentations spanned a range of applications – from cancer research to molecular biology and biomarker discovery. Of the 15 presentations, nine focused on the importance of PBIO’s PCT platform in cancer research. Three of these presentations put emphasis on the use of streamlined sample preparation protocols and systems featuring Pressure BioSciences’ Barocycler 2320EXT instrument and its associated and proprietary MicroTubes.

Data suggest that the use of the PCT platform accelerates and strengthens protein analysis, improving cancer characterization and providing clinically relevant information at the end of the trial.

Researchers from both Australia and China reported advances in their cancer diagnostic programs. These programs are reliant on the PBIO PCT platform for the rapid extraction of proteins from tumor tissues for the purpose of analysis and treatment guidance.

Pressure BioSciences PCT platform was also used in studies aiming to provide more clarity on the racial disparities in cancer. Through such studies, medical professionals could eventually start offering better early screening and detection opportunities among minority groups.

A few other presentations focused on cancer biomarker discovery and protein/molecular biology research.

“The number of PCT-related presentations at the 2019 ASMS conference significantly exceeded prior PBI records for a scientific meeting. We are gratified that the use of our PCT platform continues to expand to new investigators and laboratories worldwide, and that its use has shown great promise in critical areas of human health, such as cancer,” Pressure BioSciences Global Director of Sales and Marketing Roxanna McCloskey said in a news release.

Being featured during presentations at such a prestigious scientific event shows the increasing potential of the PCT technology in diagnostics and discovery, according to McCloskey. The Pressure BioSciences team believes that such platforms could eventually be utilized routinely in precision medicine, a field that’s expanding rapidly and is anticipated to reach a volume of $216.75 billion by 2028, according to BIS Research (http://ibn.fm/FbaSz).

Pressure BioSciences is a leader in the development of innovative pressure-based solutions for the global life sciences industry. The company’s products are based on the properties of static and alternating hydrostatic pressure. PCT is a patented technology platform that uses alternating cycles of hydrostatic pressure to control bio-molecular interactions. Pressure BioSciences’ primary goal for the platform is the development of PCT-based products for biomarker discovery, drug development, biotherapeutics, forensics and soil and plant biology, to name but a few areas of focus and interest.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Well Positioned to Address Changes in Cannabis Product Regulations

  • In line with Health Canada’s amended cannabis regulations, Supreme Cannabis has reaffirmed its expanded product strategy
  • Supreme Cannabis plans to debut a range of cannabis extract offerings, including vaping liquids, concentrates, oils and tinctures
  • Health Canada’s amended regulations permit the legal production and sale of three additional types of cannabis products, including cannabis edibles, extracts and topicals

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is prepared to meet Health Canada’s amended cannabis regulations, which include three additional types of cannabis products: cannabis edibles, extracts and topicals (http://ibn.fm/oOVOm).

The company’s strategy is to target premium brands, leverage its coast-to-coast distribution in Canada and expand into the international cannabis market. Supreme Cannabis’ expanded product strategy includes adding high-quality cannabis extracts, including vaping liquids, concentrates, oils and tinctures, to its brand portfolio.

Supreme Cannabis also plans to enter the extracts category through its agreement with vaporizer firm Pax Labs Inc. Terms of the agreement call for Supreme Cannabis subsidiary 7ACRES to become one of only four licensed producers to supply cannabis pods for the PAX Era vaporizer in Canada.

Supreme Cannabis also intends to commercialize and develop a product lineup that includes extracts and oils through its partnership with Khalifa Kush Enterprises of Canada ULC. Its proposed acquisition of Blissco Cannabis Corp. will also provide for new product development – under the Blissco brand – of oils and topicals for the wellness consumer.

Regarding the cannabis extracts market, Supreme Cannabis CEO Navdeep Dhaliwal said in a news release, “Supreme Cannabis has positioned brands, secured partnerships and developed inputs to address this meaningful segment of the market and introduce high-quality cannabis products as early as possible.” Dhaliwal added that the cannabis-extracts market represents some 35 percent of industry sales in some legal U.S. states.

New Health Canada regulations are expected to come into effect October 17, 2019. On July 15, license holders can start to submit requests for license amendments. On October 17, license holders can begin to submit new product notifications. Mid-December 2019 is the earliest anticipated date when new products can be sold, per a Health Canada release (http://ibn.fm/omcB6).

Supreme Cannabis is a Toronto-based company that is focusing on pursuing opportunities and generating sustainable growth in what it sees as an emerging global market.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

Uber Technologies Inc. (NYSE: UBER) Geared to Test Uber Eats Drone Delivery

  • The Federal Aviation Administration has granted Uber and San Diego, California, permission to test food delivery via drone services
  • Uber partnered with McDonald’s and completed the first phase of testing at San Diego State University
  • Uber made this announcement after Amazon announced similar plans to commence drone delivery services

Uber Technologies Inc. (NYSE: UBER) has completed its initial phase testing for food delivery via drones for Uber Eats (http://ibn.fm/cx2J3), at San Diego State University. This testing was done in collaboration with McDonald’s, after the Federal Aviation Administration granted Uber the drone testing rights. Uber plans to include other Uber Eats food and delivery partners in the future while leveraging the expertise and technology of Uber Elevate.

Uber Eats will use drone services for only a part of the delivery journey. Once the food is prepared as per the order placed by the customer, it will be loaded in the drone. The drone will then carry the food to a predetermined central location, from where manual deliveries will be done. Meanwhile, Uber’s Elevate Cloud Systems will monitor and guide the drones, as well as informing Uber Eats delivery drivers of the delivery points and times of food deliveries. This point of landing is likely to be the rooftop of an Uber vehicle. The delivery person will then collect and hand-deliver the food at the notified address.

In a statement released by Uber, Luke Ficher, Uber Elevate’s head of flight operations, said that the company was complying with the strict regulations and safety measures detailed by the FAA. He further stated that Uber envisions providing Uber Eats services to a greater number of people in a safe and convenient manner.

Using drone services for food delivery indicates that Uber intends to implement mammoth expansion plans. Eats is one of the most profitable ventures of Uber, recording gross booking growth of 108 percent to $3.07 billion in Q1 2019 (http://ibn.fm/lNXfL). Uber envisages extending Uber Eats services in densely populated urban areas where doorstep delivery is not feasible. With the huge network of Uber Eats delivery and restaurant partners and Uber Elevate technology, Uber is uniquely positioned to take on this challenging role.

For more information, visit the company’s website at www.Uber.com

Sharing Services Global Corporation (SHRG) Elevating its Profile Amid Direct Sales Industry Successes, Wellness Industry Growth

  • Sharing Services Global is building a social connectivity model through its growing direct sales portfolio, encouraging home-based entrepreneurship and widespread consumer activity
  • Sharing Services’ Elevacity brand is part of a $12 billion trend in wellness consumerism that provides healthy products and services
  • The direct sales industry generated $35.4 billion in retail revenues during 2018, up 1.3 percent over the prior year, and Sharing Services’ revenues have been marking record month-over-month increases

The technological revolution of the past two decades has reimagined the landscape of social experiences. People have focused a growing measure of time and work on documenting the details of their lives, whether marvelous or mundane, so they can share photos and stories with an expansive network of acquaintances via electronic media platforms. An irony of the reimagined social network is that people may be strongly connected to each other across thousands of miles while virtually unaware of other persons within close physical proximity to them at the same time.

Within the social circle revolution, direct sales’ emphasis on personalized shopping experiences has taken on a new degree of importance, as evidenced by the financial strength of direct sales innovator Sharing Services Global Corporation (OTCQB: SHRG) and its homespun Elepreneur network of independent sales associates.

Sharing Services is a multi-million-dollar operation that owns or controls an interest in companies that sell a wide array of products and services directly to the consumer, including health and wellness offerings.

The Elepreneurs elevate the company’s home-based business entrepreneurship model, furthering a model through which diverse market components work together synergistically in a common market universe.

The result of Sharing Services’ friendly, enthusiastic sales approach has been a string of monthly revenues records for the company, mirroring larger success trends for direct sellers in general.

The Direct Selling Association, a national trade association for companies that offer entrepreneurial opportunities to independent sellers, recently reported that retail sales and the number of people selling and purchasing products and services through the direct sales channel are all experiencing solid growth.

The report states that direct sales generated $35.4 billion in retail revenues during 2018, up 1.3 percent from 2017. It likewise notes that the number of direct sellers grew by 1.6 percent to more than six million people in the United States, and that there were more than 36.6 million people actively buying through direct sales channels during the year (http://ibn.fm/2mg7i).

“Retail sales were strong, thanks largely to the U.S. direct sales force and their ability to attract millions and millions of customers,” Direct Selling Association President and CEO Joseph N. Mariano stated in a release. “As we look forward and evaluate industry data, as well as national economic and retail projections, we believe the industry will continue to see modest growth during the next three years.”

The organization noted that the number of people involved in direct selling in the United States grew by 31.4 percent from 2011 to 2016, outpacing U.S. retail sales growth, and that people involved in direct selling have a higher than average percentage of annual incomes over $50,000, at 58 percent, according to Sharing Services (http://ibn.fm/c5EZl).

Wellness products and value-added services make up the most lucrative sectors of the direct selling industry. Sharing Services’ Elevacity brand, promoting such wellness products, is part of a market that commanded $12 billion in total sales during 2016.

To build on the company’s successes, Sharing Services has filed an application to uplist its stock to the Nasdaq Capital Market (http://ibn.fm/16rGf).

“We have made significant progress in strengthening our financial performance, governance and liquidity in the last 18 months since rebranding and launching our first two companies to position us for continued growth and profitability… A listing on the Nasdaq Capital Market is a natural progression for the company and our shareholders,” CEO John “JT” Thatch stated in a news release (http://ibn.fm/lVozo).

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Adds C$10 Million in Funding to California Cannabis Asset-Building Effort

  • TransCanna Holdings closed a recent round of private placement funding with aggregate gross proceeds of more than C$10 million
  • TransCanna will use the funding to help grow its statewide vertically integrated cannabis production and distribution efforts in California’s robust marketplace
  • Following an extensive search, the company has named a general manager for its 196,000-square-foot hub facility that will serve up to five satellites
  • Pending acquisition projects are expected to expand TransCanna’s asset and brand options in the state

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8), a company aiming to create and buy 15 premium brands in California, garnered aggregate gross proceeds of more than C$10 million during its just-closed round of private placement funding, which will be used to fund further equipment purchases for its vertically integrated cannabis facility in Modesto, California, as well as for additional acquisitions and other corporate purposes (http://ibn.fm/9rcrM).

TransCanna has been building a strong statewide operation in California – the largest marketplace in the global cannabis resurgence as adult lifestyle and wellness consumers drive a variety of plant-based sectors to robust financial activity. The company’s Modesto facility is a 196,000-square-foot cannabis-focused hub for its satellite operations that are expected to include integrated divisions for transportation and distribution, cultivation and nursery, lab extraction, and manufacturing and packaging. All of the activities within what is “arguably (the) largest vertically integrated cannabis focused facility in California” will be to satisfy the company’s own brands.

TransCanna believes that the highest probability of success in the cannabis marketplace centers on owning its own portfolio of premium brands, and it intends to provide all of the servicing for those brands (nursery, cultivation, manufacturing, extraction and distribution) through its self-contained eco-system. These efforts are being completed for scaling, with an aim of becoming one of the largest revenue-generating publicly traded cannabis companies in California.

The private placement round included an aggregate of more than two million units of shares and half-share purchase warrants in the company sold at C$5 per unit. The company has also engaged independent Toronto financial services organization Umbrella Capital Group Ltd. for market-making activities across a three-month term, according to TransCanna’s June 7 announcement.

The company’s plans include the development of 15 premium cannabis brands that will reach store shelves within the next two years. As part of the product-building strategy, TransCanna is working to acquire the asset packages for cannabis-infused fruit snacks producer Soldaze, high-end flower cultivator Lyted Farms and hemp-based CBD coconut oil maker Biovelle, and the new funding is expected to help advance those plans.

TransCanna recently named the general manager for its Modesto hub, which will serve up to five satellites throughout California, advancing the ramp-up of operations (http://ibn.fm/9x5iQ). Alan R. Applonie will be responsible for all activities relating to the manufacturing operations of the 196,000-square-foot facility, as well as other facilities and operations that TransCanna may acquire in Stanislaus County, according to the company.

“I’ve spent over six months interviewing for top-tier talent to oversee our operations and I firmly believe Alan is that person,” CEO Jim Pakulis stated in a news release. “Alan’s most recent position was for a multi-billion-dollar enterprise in which his division regularly produced greater than $300 million in annual revenues. We have no doubt he will add significant value to the TransCanna family of brands.”

Pakulis was featured in an eight-minute video tour of the site (http://ibn.fm/2mzVA) highlighting the company’s pride in its operations core on a 5.5-acre property parcel that the company may develop to about 400,000 square feet of new indoor growing space.

For more information, visit the company’s website at www.TransCanna.com

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

Green Hygienics Holdings Inc. (GRYN) Secures Hemp Sale Purchase Order with U.S. Tobacco de Mexico

  • Green Hygienics signed a purchase order for the sale of hemp flower to the Tijuana-based firm over the course of five years
  • Hemp flower from Green Hygienics will be used in the U.S. Tobacco de Mexico production lines; U.S. Tobacco de Mexico has over 20 brands of CBD hemp cigarettes
  • The partnership is in line with the Green Hygienics growth strategy; the company generates revenue through innovative product development, as well as through strategic partnerships and acquisitions

Green Hygienics Holdings Inc. (OTCQB: GRYN) recently announced its entry into a multiyear purchase order for the sale of hemp to U.S. Tobacco de Mexico, an industry leader with over 20 different brands of CBD hemp cigarettes (http://ibn.fm/hvFMg). The lucrative five-year contract will require Green Hygienics to deliver $56.4 million worth of hemp flower to the Tijuana, Mexico-based firm for use in its production lines.

U.S. Tobacco de Mexico is a Tijuana-based tobacco and cigarette product importer. Its excellent management team and global positioning capabilities will provide various opportunities, making the partnership an exciting one, Green Hygienics Vice President of Business Development Matt Dole said in a news release.

Green Hygienics is working on strategic collaborations and market acquisitions. These corporate moves are expected to enable the company to position itself in the best possible way as the hemp market grows.

The U.S. hemp market alone is expected to grow nearly 10 times, to over $20 billion, by 2024 (http://ibn.fm/HX0WA). Currently, the U.S. hemp product market is estimated at $1.8 billion, but legislative changes such as the passing of the federal Farm Bill are expected to allow for much quicker growth in the future.

Globally, the CBD product market is expected to reach a volume of $16.32 billion by 2026, achieving a CAGR of 27.7 percent (http://ibn.fm/u67ln). Health care innovation, clinical research and a broader acceptance of hemp-based products are all expected to contribute to the expansion. The market is segmented into food-grade and therapeutic-grade products. The therapeutics products are anticipated to continue holding the largest market share, reaching $9.3 billion by 2026.

Green Hygienics Holdings is a full-scope, premium cannabis cultivation company that targets both high-end medical and recreational adult users. Company practices are based on over 25 years of experience in agricultural science and innovation.

The Green Hygienics growth strategy is based on the generation of revenue from premium grade cannabis products, the development and licensing of valuable IP, strategic acquisitions and the creation of global consumer brands in the niche.

Scientific innovation can be used to control the conditions and the factors that determine cultivation quality. Through its developments, Green Hygienics can monitor all aspects of cannabis cultivation to maximize yields and reduce the cost per gram in relationship to what competitors are capable of offering.

Green Hygienics Company is headquartered in Las Vegas, Nevada. It is also establishing operations in San Diego to target the $5 billion California market.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) Starts Selling Cannabis Flower Commercially, Considers Wholesale Distribution

  • Sproutly Canada’s executive team recently announced the company’s first commercial sale of cannabis flower to another licensed producer in Canada
  • The sale marks a major milestone for Sproutly as the beginning of a new revenue stream that is in line with the company’s strategic expansion plans
  • Sproutly also announced that it is awaiting the receipt of a sales license, allowing the company to sell more wholesale craft flower under its new brand, Caliber

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) recently announced its first commercial sale of cannabis flower in Canada. Selling cannabis flower commercially to a recognized and licensed producer is a major milestone, Sproutly CEO Keith Dolo said in a company news release (http://ibn.fm/BqIrC). The shipment marks the beginning of a revenue stream, demonstrating the ability of the Sproutly team to bring the company’s strategy to reality, Dolo concluded.

Currently, Sproutly awaits its sales license from Health Canada. Once the license is received, followed by a thorough inspection, Sproutly may consider selling more wholesale craft flower to ensure consistent revenue generation. Following the receipt of its sales license from Health Canada, Sproutly plans to sell premium cannabis flower under its Caliber brand.

Caliber targets cannabis connoisseurs and high-end consumers. The high-quality manufacturing process and award-winning genetics typical for Sproutly are expected to enable the brand to deliver a superior cannabis experience.

Once the sales license is received, Sproutly plans to launch a Caliber brand campaign, soon to be followed by the distribution of the flower products. Both consumers and retailers will receive vital information about the product and its characteristics, as well as insights about the brand and what makes it different.

The Sproutly cannabis flower is produced by Toronto Herbal Remedies (THR), a fully owned company subsidiary. Its facility relies on modern production technologies and climate control to produce top-shelf premium cannabis flower. THR is in full production and harvesting weekly.

THR has a 16,600 square foot cultivation facility that is strategically located in the greater Toronto area. The facility received its Access to Cannabis for Medical Purposes Regulations (ACMPR) cultivation license from Health Canada in 2018. A processing license was also issued on April 1, 2019.

Sproutly Canada is on a mission to become the leading supplier of water-soluble cannabis bio-natural oils and solutions for cannabis beverage and edibles brands.

Leveraging its water-soluble bio-natural oils and solutions, Sproutly aims to deliver revolutionary brands to international markets through partnerships with well-established local consumer brands. This way, Sproutly will leverage an existing consumer base, expand brand loyalty and support distribution networks to deliver scientific breakthrough across the world.

Sproutly is mainly known for its groundbreaking, patented Aqueous Phytorecovery Process (APP). The technology replaces traditional water-compatible solutions with true and natural water solubility. This mechanism improves the body’s ability to utilize cannabinoids, making their effect almost immediate.

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF

The Cannabinoid of the Future? Hemptown USA at the Forefront of CBG’s Rise to Prominence

  • Widely known as the “mother of all cannabinoids,” cannabigerol is believed to have multiple benefits and medical applications in areas such as autoimmune conditions, cancer, pain management, inflammation and more
  • CBG oil’s market price in the U.S. is currently two to four times higher than the price of CBD oil
  • As genetic advances lead to higher yields, CBG looks set to become a prominent part of the cannabinoid market
  • Hemptown USA is working to ensure sustainable production of CBG and is positioned to produce about 40 percent of the North American supply of CBG in the near future

Cannabigerol (CBG) ranks among the cannabinoids that will potentially change the future of the cannabis product market. While CBD currently dominates the landscape, scientific advances and genetics could contribute to the rising prominence of CBG in the future.

Currently, the CBG content in most plants is very low – it remains less than one percent. However, genetics programs can boost that concentration and increase extraction yield. One of the companies at the forefront of CBG’s rise to prominence is Hemptown USA. With its 500-acre outdoor production facility in Oregon focused exclusively on CBG, and with access to over one million rare CBG seeds programmed to yield between 15 and 20 percent CBG, Hemptown is positioned to dominate the market.

The prominence of CBG is rising due to its multiple beneficial effects and a changing legislative landscape. What does the future hold for this currently rare cannabinoid? What have researchers discovered so far about it?

CBG: An Overview

CBG was discovered by Dr. Yechiel Gaoni and Professor Raphael Mechoulam in 1964. It is one of the cannabinoids exclusively produced by the cannabis plant. CBG is often called the mother of all cannabinoids, because it plays a crucial role in the synthesis of other cannabinoids.

CBG is non-psychotropic, which means that it doesn’t produce a high, like tetrahydrocannabinol (THC) does (http://ibn.fm/7Kc1o). In this sense, it is more similar to cannabidiol (CBD). THC and CBD, however, both start out as CBG in the plant. Cannabigerolic acid (CBGA) is the precursor to both of those, and, when specific enzymes in the plant break it down, it forms tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA).

In the plant, these acids are exposed to ultraviolet light and heat. This process contributes to the formation of THC, CBD and CBG (as well as other unique cannabinoids).

The nature through which these compounds are synthesized means that there will be a predominance of either THC or CBD in the plant. Scientists are currently working on the production of plants that produce more CBD and less THC. These genetic experiments have also been taken to the next level – attempting to boost the CBG yield of the plant.

The Numerous Potential Benefits of CBG

CBG is considered crucial for the cannabis industry, because clinical research so far suggests an array of important and beneficial effects.

Current literature suggests that CBG is a potent anti-inflammatory and anti-cancer agent (http://ibn.fm/VfGBR). While research has so far been limited due to the low concentrations of CBG in plants, genetic advances are giving the scientific community a chance to work with cannabigerol and test its complete range of diversified applications.

There’s some evidence that CBG is a good treatment option for anxiety and depression. In addition, it could be an effective natural option for addressing medical problems like glaucoma, inflammatory bowel disease, neurological conditions, bladder disorders and bacterial conditions.

CBG Production: Challenges to Overcome

Seed genetics play a crucial role in boosting CBG yield and making it readily available on the market. Companies like Hemptown are working hard to ensure the sustainable production of CBG. In fact, the company is projected to produce approximately 40 percent of the North American CBG supply in the near future.

The premium genetics of Hemptown seeds allow the company to grow plants to full maturity without compromising the CBG content. Usually, producers have to harvest very early in order to obtain CBG in the 1 to 2 percent range. As the plant grows, the quality of biomass improves and allows for maximized extraction efficiency. Once fully mature and ready for harvest, Hemptown’s Oregon crop is expected to yield a staggering 10 percent CBG.

Genetic work has already enabled scientists to produce the world’s first THC-free strains. These plants have high medicinal potential due to the optimal CBD and CBG concentrations (http://ibn.fm/tf2EA).

As CBG quantities in plants increase due to genetic advances, the compound will move out of the realm of the great unknown. In addition, the genetic modifications will be opening the door toward mass production due to optimized yields and more efficient processes. Steps in that direction have already been made, and it seems as though it’s only a matter of time before CBG products start dominating the market.

CBG Market Forecasts

CBG can increase the range of medicinal applications of other cannabinoids. It has been shown to have high pain relief potential (http://ibn.fm/6TUFF), while other research indicated benefits in the realm of autoimmune conditions (http://ibn.fm/pvKqP) and multiple sclerosis (http://ibn.fm/liJVd).

Companies like Hemptown are pioneers when it comes to the production of such innovative cannabinoids (http://ibn.fm/pcRvw). In 2019, the company acquired $5.5 million worth of Oregon CBD Seeds, including one million rare CBG seeds. In addition to Oregon, the company is also growing in Kentucky and Colorado, totaling just over 1,500 acres. Hemptown is projecting 2020 revenue from its 2019 harvest to exceed $200 million, and the company is planning to expand cultivation to 2,500 acres for the 2020 growing season.

Growing demand and the scarcity of CBG are determining factors for the current market dynamics. At the moment, the market price for CBG oil in the U.S. is two to four times the price of CBD oil. Pioneers such as Hemptown USA are already eyeing the multiple opportunities that CBG provides. As forecasts suggest that it’s likely that CBG will rival CBD and may even surpass its popularity in the years to come.

For more information, visit the company’s website at www.HemptownUSA.com

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Celebrates Manufacturing, Distribution Permits as Latest California Cannabis Advances

  • TransCanna Holdings is working to establish 15 premium cannabis brands during the next two years in California, the world’s largest cannabis market
  • TransCanna’s wholly owned TCM Distribution subsidiary is celebrating the recent acquisition of temporary manufacturing and distribution permits while continuing to seek state permits and permanent licenses
  • The permits advance production efforts at TransCanna’s 10,000-square-foot satellite operation in Adelanto, California
  • The City of Adelanto recently reduced taxes on cannabis transportation, lab services, cultivation enterprises and dispensaries
  • TransCanna has signed an LOI to acquire Soldaze cannabis-infused fruit snacks, which has just added to its product line with a Spicy Mango entry
  • TransCanna plans to centralize its statewide operations with a 196,000-square-foot self-contained facility in Modesto, California

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) has received manufacturing and distribution permits for its adult-use cannabis production satellite in Southern California, marking its latest step forward in building an industry empire within the world’s largest marketplace for the lifestyle culture plant.

TransCanna’s 10,000-square-foot facility in Adelanto, California, will serve as a distribution satellite for goods transported to the Southern California region from the company’s 196,000-square-foot cannabis-focused hub in Modesto. The Adelanto facility will also serve as a site for the production, packaging and distribution of pre-rolled cannabis products and other products of similar nature, according to the company’s news release about the permits (http://ibn.fm/EXz2G).

The Adelanto City Council also provided encouragement to TransCanna’s operations, voting to reduce its local taxes from five percent to one percent on cannabis transportation and lab services, five percent to three percent on dispensaries, and $5 per month per square foot down to 42 cents per month per square foot on cannabis cultivation enterprises.

With the temporary permits in hand, the company’s wholly owned subsidiary, TCM Distribution Inc., is continuing to pursue permanent licenses for cannabis manufacturing and distribution, as well as the needed state permits.

“GoodFellas, one of the entities the Company is preparing to acquire, will be transferring all revenue generating distribution and manufacturing processes to Adelanto once the facility receives its Certificate of Occupancy from the city, and state distribution and manufacturing permits,” TransCanna CEO Jim Pakulis stated in a news release. “We anticipate this being completed by the end of June.”

GoodFellas is a full-service cannabis advertising and marketing agency with established consumer demand and ‘SKU velocity’ in its brand, Daily Cannabis Goods, which launched last August. The Daily brand has three quality, half-gram pre-rolled joints, and TransCanna plans to add three more SKUs once the acquisition is complete (http://ibn.fm/jBumg).

TransCanna’s empire-building strategy includes the establishment of 15 premium brands, with some of the brands expected to reach store shelves by the end of 2019. To further that end, the company has signed a non-binding letter of intent to acquire the branding asset package Soldaze, a cannabis-infused fruit snacks producer in California. Soldaze recently announced that its award-winning fruit snack brand has begun receiving pre-orders for its new Spicy Mango line, which it intends to begin shipping next month (http://ibn.fm/OtgMa). Soldaze president and co-founder Shawn Shevlin will lead TransCanna’s newly formed branding division in overseeing statewide sales, working from TransCanna’s Modesto hub as the acquisition agreement is completed (http://ibn.fm/xBG6p).

The Modesto hub facility is a three-story, multi-purpose building that’s expected to serve up to five satellites statewide as TransCanna grows. The self-contained cannabis operation is anticipated to include integrated divisions for transportation and distribution, cultivation and nursery, lab extraction, and manufacturing and packaging on a 5.5-acre property parcel that the company envisions as holding space for about 400,000 square feet of new indoor growing operations, Pakulis said during an eight-minute video tour of the large Modesto facility for The Green Scene Podcast (http://ibn.fm/tkKSM).

“We have so much growth ahead of us, it’s crazy,” Pakulis added.

For more information, visit the company’s website at www.TransCanna.com

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

VPR Brands LP (VPRB) Led by Seasoned Industry Professionals, Boasts Impressive Revenue Growth

  • VPRB’s CEO brings to the team 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing
  • The company’s COO played a pivotal role in launching VPR Brands’ cannabis-based product division
  • VPR Brands has seen impressive quarterly results and is positioned as an up-and-coming player in the cannabis industry

VPR Brands LP (OTC: VPRB), an innovative technology holding company, has partnered with top international brands in an effort to rise to the top of the booming cannabis industry. The company’s assets include issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and electronic cigarette products and components.

The company currently boasts a strong portfolio of unique brands and is led by a team of seasoned industry professionals. CEO Kevin Frija has decades of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, he became the president and chief executive officer of Vapor Corp., one of the first publicly traded electronic-cigarette companies. In 2016, Frija purchased the brands and wholesale business assets of Vapor Corp., which is now owned by VPR Brands. He currently leads VPR Brands as it creates inroads into the cannabis industry, a move that is bringing the company increasing sales and profit margins.

Chief Operating Officer Dan Hoff brings valuable experience working in the vaporizer and e-cigarette industry to VPR Brands. He has held various leadership positions at Vapor Corp., including overseeing financial management, accounting functions, supply chain management, product design and development, and key vendor relations. His role in the construction and expansion of VPR Brands’ cannabis-based product division has been instrumental in helping the company pivot toward cannabis products.

VPR Brands’ industry potential has been flying under the radar, but, owing to its experienced leadership and strong brand portfolio, the company has posted impressive quarterly results. First-quarter 2019 results revealed increased revenues, indicating a nearly 31 percent year-over-year increase to $1.3 million. Additionally, the company lowered its net loss from approximately $149,000 in 2018 to approximately $138,000 in 2019 (http://ibn.fm/rSa7Z). The company continues to maintain strong gross operating margins above 40 percent.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

Last Tweets

Follow us: @Buy_Stocks_Now

From Our Blog

Pressure BioSciences Inc.’s (PBIO) PCT Platform Featured in 15 Independent Scientific Presentations

June 24, 2019

The presentations were held during the annual American Society of Mass Spectrometry conference – an event attended by more than 10,000 scientists Research focused on a wide range of applications ranging from cancer research to biomarker discovery The number of PCT-related presentations during the 2019 conference exceeded prior Pressure BioSciences records for a scientific meeting, […]

Rotate your device 90° to view site.